Needham Maintains Buy on Cellebrite DI, Raises Price Target to $17
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Mike Cikos maintains a Buy rating on Cellebrite DI (NASDAQ:CLBT) and raises the price target from $14 to $17.
August 16, 2024 | 9:31 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Mike Cikos maintains a Buy rating on Cellebrite DI and raises the price target from $14 to $17.
The raised price target from $14 to $17 by a reputable analyst is likely to positively impact the stock price of Cellebrite DI in the short term as it reflects increased confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100